Celyad Oncology SA – LSE:0QFK.L
Celyad Oncology SA stock price today
Celyad Oncology SA stock price monthly change
Celyad Oncology SA stock price quarterly change
Celyad Oncology SA stock price yearly change
Celyad Oncology SA key metrics
Market Cap | 29.45M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -0.41 |
Revenue | 124K |
EBITDA | -12.16M |
Income | -10.31M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -9808.87% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCelyad Oncology SA stock price history
Celyad Oncology SA stock forecast
Celyad Oncology SA financial statements
| Mar 2023 | 22K | -1.87M | -8500% |
|---|---|---|---|
| Jun 2023 | 44K | -3.74M | -8500% |
| Sep 2023 | 29K | -2.35M | -8117.24% |
| Dec 2023 | 29K | -2.35M | -8117.24% |
| Mar 2023 | 12178000 | 11.15M | 91.63% |
|---|---|---|---|
| Jun 2023 | 12178000 | 11.15M | 91.63% |
| Sep 2023 | 16282000 | 9.97M | 61.28% |
| Dec 2023 | 16282000 | 9.97M | 61.28% |
| Mar 2023 | -4.16M | 482.5K | -51K |
|---|---|---|---|
| Jun 2023 | -8.33M | 965K | -102K |
| Sep 2023 | -3.43M | -279K | 4.72M |
| Dec 2023 | -3.43M | -279K | 4.72M |
Celyad Oncology SA alternative data
| Aug 2023 | 35 |
|---|---|
| Sep 2023 | 35 |
| Oct 2023 | 35 |
| Nov 2023 | 35 |
| Dec 2023 | 35 |
| Jan 2024 | 35 |
| Feb 2024 | 35 |
| Mar 2024 | 35 |
| Apr 2024 | 35 |
| May 2024 | 17 |
| Jun 2024 | 17 |
| Jul 2024 | 17 |
Celyad Oncology SA other data
| Insider | Compensation |
|---|---|
Mr. Filippo Joseph Petti (1976) Chief Executive Officer, Chief Financial Officer & Director | $559,620 |
Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME, MBA (1956) Co-Founder & Independent Chairman | $85,000 |
Nicolas Van Hoecke Director of Investor Relations & Communications | |
Mr. Philippe Dechamps Chief Legal Officer | |
Mr. Philippe Nobels Vice President of HR | |
Dr. Stephen Rubino Ph.D. Chief Bus. Officer | |
Dr. Elena Spanjaard Head of Regulatory Affairs & Quality Assurance | |
Dr. Peggy Sotiropoulou Head of R&D | |
Dr. Frédéric Lehmann Vice President of Clinical Devel. & Medical Affairs | |
Dr. David Edward Gilham Chief Scientific Officer |
-
What's the price of Celyad Oncology SA stock today?
One share of Celyad Oncology SA stock can currently be purchased for approximately $3.44.
-
When is Celyad Oncology SA's next earnings date?
Unfortunately, Celyad Oncology SA's (0QFK.L) next earnings date is currently unknown.
-
Does Celyad Oncology SA pay dividends?
No, Celyad Oncology SA does not pay dividends.
-
How much money does Celyad Oncology SA make?
Celyad Oncology SA has a market capitalization of 29.45M.
-
What is Celyad Oncology SA's stock symbol?
Celyad Oncology SA is traded on the LSE under the ticker symbol "0QFK.L".
-
What is Celyad Oncology SA's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Celyad Oncology SA?
Shares of Celyad Oncology SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Celyad Oncology SA's key executives?
Celyad Oncology SA's management team includes the following people:
- Mr. Filippo Joseph Petti Chief Executive Officer, Chief Financial Officer & Director(age: 49, pay: $559,620)
- Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME, MBA Co-Founder & Independent Chairman(age: 69, pay: $85,000)
- Nicolas Van Hoecke Director of Investor Relations & Communications
- Mr. Philippe Dechamps Chief Legal Officer
- Mr. Philippe Nobels Vice President of HR
- Dr. Stephen Rubino Ph.D. Chief Bus. Officer
- Dr. Elena Spanjaard Head of Regulatory Affairs & Quality Assurance
- Dr. Peggy Sotiropoulou Head of R&D
- Dr. Frédéric Lehmann Vice President of Clinical Devel. & Medical Affairs
- Dr. David Edward Gilham Chief Scientific Officer
-
Is Celyad Oncology SA founder-led company?
Yes, Celyad Oncology SA is a company led by its founder Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME, MBA.
-
How many employees does Celyad Oncology SA have?
As Jul 2024, Celyad Oncology SA employs 17 workers, which is 51% less then previous quarter.
-
When Celyad Oncology SA went public?
Celyad Oncology SA is publicly traded company for more then 11 years since IPO on 8 Jan 2014.
-
What is Celyad Oncology SA's official website?
The official website for Celyad Oncology SA is celyad.com.
-
How can i contact Celyad Oncology SA?
Celyad Oncology SA can be reached via phone at +32 10 39 41 00.
Celyad Oncology SA company profile:
Celyad Oncology SA
celyad.comLSE
17
Medical - Pharmaceuticals
Healthcare
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Mont-Saint-Guibert, 1435
:
ISIN: BE0974260896
:
